Brain Cancer Trial, Recruiting NCT07119294 Sponsor: Jules Bordet Institute Condition: Brain Cancer
Back to Brain Cancer

Brain Cancer Trial, Recruiting

NCT07119294
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older
  • People who have a brain lesion that brain scans suggest may be glioblastoma (a type of brain tumour), or whose glioblastoma may have come back
  • People whose general health and ability to carry out daily activities falls within an acceptable range as rated by a doctor (confirm with trial site for specific details)
  • People who have signed a consent form before any study-related procedures take place

Who may not be able to join:

  • Women who are pregnant or breastfeeding
  • People who have a significant medical, neurological, psychiatric, or surgical condition that is not currently under control and that, in the lead doctor's opinion, could interfere with completing the study
  • People who experience claustrophobia (discomfort or anxiety in enclosed spaces, such as a scanner)
  • People with a known allergic or sensitivity reaction to the study imaging agent (FAPI), any of its ingredients, or to the type of dye used in MRI scans (gadolinium-based contrast agents)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 02.555.81.93

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Jules Bordet Institute
Registry
ClinicalTrials.gov
Start date
1 August 2025
Est. completion
1 December 2027

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

To compare the FAPI uptake within the tumor using quantitative measures (SUVmax, SUVmean, and volume) with the uptake of other markers of local tumor aggressiveness such as amino-acid PET and MRI data.; To compare FAPI tumor uptake (SUVmax, SUVmean) with FAP expression based on anatomopathological analysis (Immunohistochemistry) from targeted brain biopsy samples or material from ablative surgery

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov